Sigmagos – Sigma1-receptor agonists as new therapeutic agents for neuro-degenerative diseases
Sigma-receptors have been in the focus of drug discovery
for several years, being classified into two subtypes, sigma1- and sigma2-receptors. The sigma1-receptor is expressed in many different tissue types and is particularly concentrated in certain regions of the central nervous system. Therefore, it represents a new and different avenue in the possible pharmacological t reatment of brain related disorders. Several studies have shown that selective agonists of the sigma1-receptor affect higherordered brain functions such as learning and memory, cognition and mood. These studies indicate that sigma1- receptor agonists may exert therapeutic effects in dementia, depression, parkinsonism and neuropathic pain. Sigma ligands are also able to modulate endothelial cell proliferation and to control angiogenesis which makes them a promising target for oncology applications. Another area currently being investigated comprises the treatment of immune system disorders.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Lighting up the future
New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…
Researchers crack sugarcane’s complex genetic code
Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….
Evolution of the most powerful ocean current on Earth
The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….